DNA DAMAGE AND REPAIR MECHANISMS: MOLECULAR BASIS OF GENOMIC INSTABILITY AND CANCER DEVELOPMENT
Keywords:
DNA, DNA damage, DNA repair, genomic instability, mutation, cancer, MMR, BRCA1, BRCA2, chromothripsis, molecular biomarker.Abstract
DNA is the fundamental biological molecule responsible for storing, transmitting, and passing genetic information to daughter cells. Throughout the life of a cell, DNA is continuously exposed to various forms of damage caused by both endogenous metabolic processes and external environmental factors. The timely detection and removal of such damage are essential for maintaining genomic stability. The primary function of DNA repair systems is to prevent the accumulation of mutations by restoring damaged genetic material. Impairment of these repair mechanisms can lead to genomic instability, the accumulation of mutations, and alterations in the activity of genes that regulate cell growth. Consequently, the activation of oncogenes, the inactivation of tumor suppressor genes, and the disruption of cell cycle control can contribute to cancer development. This article examines the major types of DNA damage, DNA damage response mechanisms, and principal DNA repair pathways, as well as the role of their dysfunction in genomic instability and cancer pathogenesis. Furthermore, it discusses the mismatch repair system, repair defects associated with BRCA1 and BRCA2, chromothripsis, and the potential use of DNA repair mechanisms as molecular targets in cancer treatment. A comprehensive understanding of the molecular characteristics of DNA repair provides an important scientific basis for improving early cancer detection, molecular classification, and personalized treatment strategies.
References
1.Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
2.Groelly F.J., Fawkes M., Dagg R.A., et al. Targeting DNA damage response pathways in cancer. Nature Reviews Cancer. 2023;23:78–94.
3.Ngoi N.Y.L., Pilié P.G., McGrail D.J., et al. Targeting ATR in patients with cancer. Nature Reviews Clinical Oncology. 2024;21:278–293.
4.Drew Y., Zenke F.T., Curtin N.J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nature Reviews Drug Discovery. 2025;24:19–39.
5.Li J., Jia Z., Dong L., et al. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomarker Research. 2024;12:111.
6.Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917.
7.Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921.
8.Lord C.J., Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–1158.
9.The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors. npj Precision Oncology. 2024;8:190.
10.Yang K., Zhu L., Liu C., et al. Current status and prospect of the DNA double-strand break repair pathway in colorectal cancer development and treatment. Biochimica et Biophysica Acta – Molecular Basis of Disease. 2024;1870:167438.
11.Al-Rawi D.H., Lettera E., Li J., et al. Targeting chromosomal instability in patients with cancer. Nature Reviews Clinical Oncology. 2024;21:645–659.
12.Boveri and beyond: Chromothripsis and genomic instability from mitotic errors. Molecular Cell. 2024;84:55–69.
13.Yan X., Mischel P., Chang H. Extrachromosomal DNA in cancer. Nature Reviews Cancer. 2024;24:261–273.
14.Fugger K., Hewitt G., West S.C., Boulton S.J. Tackling PARP inhibitor resistance. Trends in Cancer. 2021;7:1102–1118.
15.PARPi, BRCA, and gaps: controversies and future research. Trends in Cancer. 2024;10(9):857–869.
16.BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. British Journal of Cancer. 2024;131:1400–1414.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal